The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Abstract
PURPOSE: To describe the incidence of acute neurotoxicity (NT) in children with lower risk B-precursor acute lymphoid leukemia (ALL) treated with intermediate-dose methotrexate (MTX) or divided dose oral MTX with or without intravenous (i.v.) mercaptopurine (MP) and extended intrathecal triple therapy. PATIENTS AND METHODS: Thirteen hundred four patients were entered onto Pediatric Oncology Group (POG) 9005, a randomized phase III trial, between January 11, 1991 and September 1, 1994. After remission induction, patients were randomized to one of three 24-week intensification schedules: regimen A, MTX 1,000 mg/m2 i.v. infused over 24 hours and MP 1,000 mg/m2 i.v. infused over 6 hours; regimen B, low-dose repetitive MTX 30 mg/m2 orally every 6 hours for six doses and i.v. MP; or regimen C, i.v. MTX alone. Intensification was given every 2 weeks for 12 courses. CNS prophylaxis was age-adjusted intrathecal MTX (ITM). In August 1992, the CNS prophylaxis was changed to age-adjusted triple intrathecal therapy (TIT). Reports of grades 3 and 4 acute NT were reviewed. RESULTS: Acute NT was reported in 95 of 1,218 (7.8%) eligible patients treated on POG 9005. The incidence by regimen was regimen A, 46 of 543 patients (8.3%); regimen B, 13 of 354 patients (3.7%); and regimen C, 36 of 321 patients (11.2%) (P < .001). The majority of events were seizures and the median number of days to first occurrence of symptomatic NT after ITM or TIT was 10 to 11 days. Computed tomography (CT) or magnetic resonance imaging (MRI) evidence consistent with leukoencephalopathy (LE), with or without the presence of cerebral calcifications, was observed in 75% and 77.1 % of symptomatic patients treated on regimens A and C, respectively, but in only 15.4% of symptomatic patients treated on regimen B (P < .001). Factors associated with an increased incidence of NT included increased cumulative exposure with repeated i.v. MTX (regimens A and C v B), increased MTX-leucovorin (LCV) ratio (regimens A and C v B), and choice and timing of TIT therapy. The use of i.v. MP during intensification did not appear to contribute to these complications. The switch to TIT CNS prophylaxis was associated with an inferior overall 4-year continuous complete remission (CCR) (P=.031) when compared with ITM. CONCLUSION: Intensification with repeated i.v. MTX in the setting of low-dose LCV rescue was associated with a higher risk for acute NT and LE, especially in patients who received concomitant TIT. The long-term consequences for affected patients remain unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Folic acid—an innocuous means to reduce plasma homocysteine
Brattström, L. E., Israelsson, B., Jeppsson, J.-O., & Hultberg, B. L. (1988) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365518809167487 · Cited by 363
Peylan-Ramu, N., Poplack, D. G., Pizzo, P. A., Adornato, B. T., & Di Chiro, G. (1978) · New England Journal of Medicine · doi:10.1056/nejm197804132981504 · Cited by 294
Ochs, J., Mulhern, R., Fairclough, D., Parvey, L., Whitaker, J., Ch'ien, L., Mauer, A., & Simone, J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.1.145 · Cited by 283
Veerman, A. J., Hählen, K., Kamps, W. A., Van Leeuwen, E. F., De Vaan, G. A., Solbu, G., Suciu, S., Van Wering, E. R., & Van der Does-Van der Berg, A. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.911 · Cited by 204
Quinn, C. T., Griener, J. C., Bottiglieri, T., Hyland, K., Farrow, A., & Kamen, B. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2800 · Cited by 189
Rowland, J. H., Glidewell, O. J., Sibley, R. F., Holland, J. C., Tull, R., Berman, A., Brecher, M. L., Harris, M., Glicksman, A. S., & Forman, E. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.12.1327 · Cited by 180
Neuropsychologic effects of chemotherapy on children with cancer: a longitudinal study.
Copeland, D. R., Moore, B. D., Francis, D. J., Jaffe, N., & Culbert, S. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2826 · Cited by 167
Transient cerebral dysfunction secondary to high-dose methotrexate.
Walker, R. W., Allen, J. C., Rosen, G., & Caparros, B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1845 · Cited by 159
Waber, D. P., Tarbell, N. J., Fairclough, D. C., Atmore, K., Castro, R., Isquith, P. Κ., Lussier, F., Romero, I., Carpenter, P. J., & Schiller, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2490 · Cited by 159
Cited by
Acute Lymphoblastic Leukemia in Children
Hunger, S. P., & Mullighan, C. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1400972 · Cited by 2,204
Preventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Pui, C.-H., & Evans, W. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390907 · Cited by 832
Schrappe, M., Reiter, A., Ludwig, W. D., Harbott, J., Zimmermann, M., Hiddemann, W., Niemeyer, C. M., Henze, G., Feldges, A., Zintl, F., et al. (2000) · PubMed · doi:10.1182/blood.v95.11.3310 · Cited by 602
Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia
Bhojwani, D., Sabin, N. D., Pei, D., Yang, J. J., Khan, R. B., Panetta, J. C., Krull, K. R., Inaba, H., Rubnitz, J. E., Metzger, M. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0808 · Cited by 400
Metadata
- Authors
- Mahoney, D. H., Shuster, J. J., Nitschke, R., Lauer, S. J., Steuber, C. P., Winick, N., & Camitta, B.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-05
- Volume
- 16
- Issue
- 5
- Pages
- 1712-1722
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2226649616
- Cited by
- 290
- References
- 26
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. https://app.cochat.ai/papers/10.1200/jco.1998.16.5.1712
- The paper
- Mahoney, D. H., Shuster, J. J., Nitschke, R., Lauer, S. J., Steuber, C. P., Winick, N., & Camitta, B. (1998). Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.5.1712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.